Citations

Clear

1432 citation(s) found for "Uk, Nathan".

SENESCENCE SECRETOME: BIOMARKERS OF BIOLOGICAL AGING AND POSTOPERATIVE OUTCOMES
White, Thomas A. , Atkinson, Elizabeth J. , Burning, Michelle, Schafer, Marissa , Zhang, Xu , Kumar, Amanika , LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | November 11, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: S98-S98

10.1093/geroni/igz038.370 Get It

Abstract Senescent cells drive age-related tissue dysfunction through their potent secretome, termed the senescence associated secretory phenotype (SASP). Circulating concentrations of SASP factors may reflect biological age and serve as clinically useful biomarkers of surgical risk and ultimately, surrogate endpoints in clinical trials. However, they remain largely uncharacterized. We tested associations between circulating concentrations of SASP proteins and biological age, as determined by the accumulation of age-related health deficits, and/or postoperative outcomes in a sample of residents in Olmstead County, MN, age 60-90 years (n = 115) and cohorts of older adults undergoing surgery for severe aortic stenosis (prospective; n = 97) or ovarian cancer (case-control; n = 36). Circulating concentrations of SASP factors were associated with biological age and adverse postoperative outcomes, including risk of any adverse event or rehospitalization within the year following surgery (aortic stenosis group) or admission to an intensive care unit within 30 days of hospital discharge (ovarian cancer group). Gradient boosting machine modeling revealed a panel of SASP factors that predicted adverse outcomes across both surgical groups better than biological age or chronological age and sex. This suggests that the circulating SASP is a robust indicator of age-related health status and may help guide clinical decision making. Furthermore, circulating SASP factors may be harnessed as a readily quantifiable biomarkers in senescence-targeting interventional human studies.
SENOLYTIC DRUGS: DISCOVERY, TRANSLATION, AND APPLICATION
LeBrasseur, Nathan K.

Mayo Clinic

Innovation in Aging | November 9, 2019 | Volume: 3 | Issue: Supplement_1 | Pages: S745-S745

10.1093/geroni/igz038.2730 Get It

Abstract Diverse forms of molecular and cellular stress trigger senescence, a state of growth arrest in proliferation-competent cells that is often accompanied by a robust secretory phenotype. Senescent cell burden increases with age in multiple tissues and, plausibly, contributes to the pathogenesis of age-related diseases and geriatric syndromes. Discovery science efforts have identified druggable targets in senescent cells, including key nodes in anti-apoptosis pathways, that distinguish them from non-senescent counterparts and enable pharmacological approaches for their selective elimination. The therapeutic potential of senolytic interventions to improve health- and lifespan has been supported by translational research studies, including murine models of aging, atherosclerosis, osteoporosis, neurodegeneration, pulmonary fibrosis, and frailty. These studies have informed the design of first-in-human clinical trials of senolytic drugs, which have recently begun. The objective of this lecture is to highlight both the progress and challenges of advancing interventions targeting senescent cells from bench to bedside.
Associations between hematology/oncology fellows’ training and mentorship experiences and hematology-only career plans
Masselink, Leah E. , Erikson, Clese , Connell, Nathan T. , Castro, Laura M. De , Dent, Georgette A. , Marshall, Ariela L. , Naik, Rakhi P. , Nelson, Marquita , Rajasekhar, Anita, Sharma, Deva , Smith, Melody , Lee, Alfred Ian , Marshall, Ariela , Smith, Melody , O'Connell, Casey Lee

Mayo Clinic

Blood Advances | October 31, 2019 | Volume: 3 | Issue: 21 | Pages: 3278-3286

10.1182/bloodadvances.2019000569 | PMID 31698456 Get It

Key PointsClinical, research and mentorship experiences in hematology are positively associated with fellows' plans to pursue hematology-only careers.
The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence
Chandrasekar, Aswath P. , Cummins, Nathan W. , Badley, Andrew D. , Cummins, Nathan W , Badley, Andrew D

Mayo Clinic

Clinical Microbiology Reviews | October 29, 2019 | Volume: 33 | Issue: 1 | Pages: No page available

10.1128/cmr.00107-19 | PMID 31666279 Get It

Advances in HIV-1 therapy have transformed the once fatal infection into a manageable, chronic condition, yet the search for a widely applicable approach to cure remains elusive. The ineffectiveness of antiretroviral therapy (ART) in reducing the size of the HIV-1 latent reservoir has prompted investigation into the mechanisms of HIV-1 latency and immune escape.
Mechanisms of Human Immunodeficiency Virus-Associated Lymphocyte Regulated Cell Death
Paim, Ana C. , Badley, Andrew D. , Badley, Andrew D , Cummins, Nathan W.

Mayo Clinic

AIDS Research and Human Retroviruses | October 29, 2019 | Volume: 36 | Issue: 2 | Pages: 101-115

10.1089/aid.2019.0213 | PMID 31659912 Get It

Systemic Safety of a Recombinant AAV8 Vector for Human Cocaine Hydrolase Gene Therapy: A Good Laboratory Practice Preclinical Study in Mice
Chen, Vicky Ping , Gao, Yang , Geng, Liyi, Steele, Mike, Jenks, Nathan, Peng, Kah-Whye , Brimijoin, Stephen , Jenks, Nathan J.

Mayo Clinic

Human Gene Therapy | October 25, 2019 | Volume: 31 | Issue: 1-2 | Pages: 70-79

10.1089/hum.2019.233 | PMID 31650869 Get It

Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment
Staff, Nathan P. , Cavaletti, Guido , Islam, Badrul , Lustberg, Maryam B. , Psimaras, Dimitri , Tamburin, Stefano , Staff, Nathan P , Lustberg, Maryam

Mayo Clinic

Journal of the Peripheral Nervous System | October 24, 2019 | Volume: 24 | Issue: S2 | Pages: No page available

10.1111/jns.12335 | PMID 31647151 Get It

AbstractPlatinum‐induced peripheral neurotoxicity (PIPN) is a common side effect of platinum‐based chemotherapy that may cause dose reduction and discontinuation, with oxaliplatin being more neurotoxic. PIPN includes acute neurotoxicity restricted to oxaliplatin, and chronic non‐length‐dependent sensory neuronopathy with positive and negative sensory symptoms and neuropathic pain in both upper and lower limbs. Chronic sensory axonal neuropathy manifesting as stocking‐and‐glove distribution is also frequent. Worsening of neuropathic symptoms after completing the last chemotherapy course may occur. Motor and autonomic involvement is uncommon. Ototoxicity is frequent in children and more commonly to cisplatin. Platinum‐based compounds result in more prolonged neuropathic symptoms in comparison to other chemotherapy agents. Patient reported outcomes questionnaires, clinical evaluation and instrumental tools offer complementary information in PIPN. Electrodiagnostic features include diffusely reduced/abolished sensory action potentials, in keeping with a sensory neuronopathy. PIPN is dependent on cumulative dose but there is a large variability in its occurrence. The search for additional risk factors for PIPN has thus far yielded no consistent findings. There are currently no neuroprotective strategies to reduce the risk of PIPN, and symptomatic treatment is limited to duloxetine that was found effective in a single phase III intervention study. This review critically examines the pathogenesis, incidence, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of PIPN.
Vinca alkaloids, thalidomide and eribulin‐induced peripheral neurotoxicity: From pathogenesis to treatment
Islam, Badrul , Lustberg, Maryam B. , Staff, Nathan P. , Kolb, Noah , Alberti, Paola , Argyriou, Andreas A. , Kolb, Noah A , Staff, Nathan P , Lustberg, Maryam

Mayo Clinic

Journal of the Peripheral Nervous System | October 24, 2019 | Volume: 24 | Issue: S2 | Pages: No page available

10.1111/jns.12334 | PMID 31647152 Get It

AbstractVinca alkaloids, thalidomide, and eribulin are widely used to treat patients with childhood acute lymphoblastic leukemia (ALL), adults affected by multiple myeloma and locally invasive or metastatic breast cancer, respectively. However, soon after their introduction into clinical practice, chemotherapy‐induced peripheral neurotoxicity (CIPN) emerged as their main non‐hematological and among dose‐limiting adverse events. It is generally perceived that vinca alkaloids and the antiangiogenic agent thalidomide are more neurotoxic, compared to eribulin. The exposure to these chemotherapeutic agents is associated with an axonal, length‐dependent, sensory polyneuropathy of mild to moderate severity, whereas it is considered that the peripheral nerve damage, unless severe, usually resolves soon after treatment discontinuation. Advanced age, high initial and prolonged dosing, coadministration of other neurotoxic chemotherapeutic agents and pre‐existing neuropathy are the common risk factors. Pharmacogenetic biomarkers might be used to define patients at increased susceptibility of CIPN. Currently, there is no established therapy for CIPN prevention or treatment; symptomatic treatment for neuropathic pain and dose reduction or withdrawal in severe cases is considered, at the cost of reduced cancer therapeutic efficacy. This review critically examines the pathogenesis, epidemiology, risk factors (both clinical and pharmacogenetic), clinical phenotype and management of CIPN as a result of exposure to vinca alkaloids, thalidomide and its analogue lenalidomide as also eribulin.
Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue
Cavaletti, Guido , Alberti, Paola , Argyriou, Andreas A. , Lustberg, Maryam B. , Staff, Nathan P. , Tamburin, Stefano , Staff, Nathan P , Lustberg, Maryam

Mayo Clinic

Journal of the Peripheral Nervous System | October 24, 2019 | Volume: 24 | Issue: S2 | Pages: No page available

10.1111/jns.12337 | PMID 31647155 Get It

Abstract Chemotherapy‐induced peripheral neurotoxicity (CIPN) is a potentially dose‐limiting side effect of several commonly used cytotoxic chemotherapy agents. The main pharmacological classes that may cause CIPN include classical anticancer drugs, as well as the recently introduced immune checkpoint inhibitors and antibody drug conjugates. The absence of a complete knowledge of CIPN pathophysiology is only one of the several unsolved issues related to CIPN. Among some of the most relevant aspects of CIPN deserving further attention include the real number of patients exposed to the risk of CIPN, the long‐term impact on cancer survivors' quality of life due to incomplete recovery from CIPN, the economic burden related to acute and chronic CIPN, and the different perspective and education of the healthcare specialists in charge of managing patients with CIPN. Overall, CIPN remains a very challenging area of research as there are still several unresolved issues to be addressed in the future. In this special issue, the multifaceted profile of CIPN will be presented, with particular emphasis on bolstering the need to develop more optimized outcome measures than the existing ones to accurately evaluate the extent of CIPN, but also to ascertain the differences in the incidence, risk factors, clinical phenotype, and management of CIPN, according to the most commonly used neurotoxic chemotherapy classes. Perspectives for future research to pursue in order to cover the gaps in knowledge in the CIPN field will also be discussed.
1503. Engraftment of Investigational Microbiome Drug, SER-262, in Subjects Receiving Vancomycin Is Associated with Reduced Rates of Recurrence after Primary Clostridium Difficile Infection (CDI)
Ford, Christopher B. , Litcofsky, Kevin , McGovern, Barbara , Pardi, Darrell S. , Nathan, Richard, Hansen, Val, Brennan, Robert T. , Pullman, John, Bernardo, Patricia, Tomlinson, Amelia D., Bryant, Jessica A. , Walsh, Emily , Rodriguez, Michelle, Rogalin, Henry B., Henn, Matt, Brennan, Robert, Horgan, Kevin, Wang, Elaine

Mayo Clinic

Open Forum Infectious Diseases | October 23, 2019 | Volume: 6 | Issue: Supplement_2 | Pages: S547-S548

10.1093/ofid/ofz360.1367 Get It

Abstract Background CDI is a 2-hit process requiring C. difficile spores and antibiotic-mediated dysbiosis, a low diversity state of the gut microbiome. Recurrent CDI (rCDI) is common and may be related to inadequate antibiotic concentrations (e.g., metronidazole; MET) or persistent dysbiosis (e.g., vancomycin; VAN). SER-262 is an oral investigational microbiome drug rationally designed to reduce rCDI by restoring colonization resistance. Methods SERES-262-001 was a Phase 1b randomized placebo (PBO)-controlled single and multidose study. Subjects with primary CDI (n = 96) were enrolled in 8 cohorts (SER-262: PBO, 5:1). Subjects were dosed after MET (n = 57) or VAN (n = 39) per investigator discretion. Engraftment of SER-262 strains was evaluated using strain-specific molecular probes in fecal samples; microbial diversity was measured via whole metagenomic shotgun sequencing. Endpoints included safety and rCDI rates up to 8 weeks posttreatment and strain engraftment at 1, 4, 8, 12, and 24 weeks. Results SER-262 safety was comparable to PBO. Although overall rCDI rates were similar in SER-262 (n = 80) and PBO (n = 16) subjects (18.8% vs. 12.5%, respectively), in a post-hoc analysis we observed reduced rates of rCDI in the VAN+SER-262 arm compared with MET+SER-262 (6.3 vs. 27.1%, respectively, P = 0.02, Figure 1). Overall, 8 of 12 SER-262 strains showed significant engraftment relative to PBO. However, greater SER-262 strain engraftment was observed in VAN-treated subjects compared with MET-treated subjects (P < 0.001, Figure 2). To better understand the impact of dysbiosis on engraftment, we evaluated baseline microbial diversity by prior antibiotic received and observed that the diversity of Bacteroidetes and Firmicute species was lower in VAN-treated subjects compared with MET-treated subjects (P < 0.001, Figure 3). Conclusion In this first phase 1b study of a fermented microbiome drug in subjects with primary CDI, SER-262 was safe and well-tolerated. The higher efficacy rates of SER-262 in reducing rCDI among VAN-treated subjects may be due to low baseline microbial diversity, which creates an ecologic niche for greater engraftment of dose species. Treatment of C. difficile with VAN, followed by restoration of colonization resistance with SER-262, is a promising 2-pronged therapeutic paradigm to reduce rCDI. Disclosures All authors: No reported disclosures.